Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Specifically, CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited.

The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027. Patients who are more obese may ultimately do better with Zepbound, said ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

Eli Lilly continues to dominate the obesity market with Zepbound ... share — currently around 70-75% of new patients — and strong momentum suggest the company will easily absorb the impact. ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...